These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23458163)

  • 1. Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings.
    Leal GN; de Paula AC; Morhy SS; Andrade JL; Kim CA
    Cardiol Young; 2014 Apr; 24(2):229-35. PubMed ID: 23458163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study.
    McGill JJ; Inwood AC; Coman DJ; Lipke ML; de Lore D; Swiedler SJ; Hopwood JJ
    Clin Genet; 2010 May; 77(5):492-8. PubMed ID: 19968667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
    Furujo M; Kubo T; Kosuga M; Okuyama T
    Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short Communication Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings.
    Franco JF; Soares DC; Torres LC; Leal GN; Cunha MT; Honjo RS; Bertola DR; Kim CA
    Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26910003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
    Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
    Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI].
    Azak E; Gündüz M
    Turk Kardiyol Dern Ars; 2019 Oct; 47(7):587-593. PubMed ID: 31582674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
    Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
    Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
    Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
    J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
    Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.
    Braunlin E; Rosenfeld H; Kampmann C; Johnson J; Beck M; Giugliani R; Guffon N; Ketteridge D; Sá Miranda CM; Scarpa M; Schwartz IV; Leão Teles E; Wraith JE; Barrios P; Dias da Silva E; Kurio G; Richardson M; Gildengorin G; Hopwood JJ; Imperiale M; Schatz A; Decker C; Harmatz P;
    J Inherit Metab Dis; 2013 Mar; 36(2):385-94. PubMed ID: 22669363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
    Politei J; Schenone A; Blanco M; Szlago M
    Arch Argent Pediatr; 2014 Jun; 112(3):258-62. PubMed ID: 24862809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
    Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
    Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P
    Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
    Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
    Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
    Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation.
    Honjo RS; Vaca ECN; Leal GN; Abellan DM; Ikari NM; Jatene MB; Martins AM; Kim CA
    BMC Med Genet; 2020 Feb; 21(1):37. PubMed ID: 32075597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.